Clinical trials: Post-Surgical Ocular Pain
Post Surgical Ocular Inflammation
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
- Trial name
- NCT04222725
- Testing
- TRS01 eye drops
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Tarsier Pharma
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02736175
- Testing
- Dexamethasone
- Volunteers
- 438 people
- Sponsor
- Ocular Therapeutix, Inc.
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02235272
- Testing
- XG-102
- Where
- United States
- Volunteers
- 339 people
- Sponsor
- Xigen SA
Post Ocular Surgical Inflammation and Pain
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone…
- Trial name
- NCT02034019
- Testing
- Dexamethasone, Punctum Plug
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Ocular Therapeutix, Inc.
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Postoperative Ocular Pain After PRK Surgery
Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery
The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as…
- Trial name
- NCT02961062
- Testing
- SAF312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Postoperative Ocular Inflammation, Postoperative Ocular Pain
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
This study is designed to evaluate the safety and efficacy of TRIESENCE® (triamcinolone acetonide injectable suspension) in patients undergoing ophthalmic procedures.
- Trial name
- NCT07832552
- Testing
- TRIESENCE (triamcinolone acetonide injectable suspension)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Harrow Inc
Pain
Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics
The purpose of this study is to evaluate Vitrase as an adjuvant to increase absorption and dispersion of other injected anesthetics
- Trial name
- NCT00198549
- Testing
- Vitrase (ovine hyaluronidase) Lyophilized
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
Confirmatory Study Nepafenac 0.3%
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01109173
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle
- Where
- United States
- Volunteers
- 2,120 people
- Sponsor
- Alcon Research
Cataracts Infantile
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Multicenter, randomized, evaluator-blinded clinical trial compared to Prednisolone acetate, 1% in the treatment of inflammation and pain after cataract surgery in pediatric population.
- Trial name
- CLOSE-3 (NCT05724446)
- Testing
- Clobetasol Propionate, Prednisolone acetate ophthalmic suspension, 1%
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Salvat
Pterygium, Ocular Pain
Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Title of the study Efficacy and safety of PRO-155 (Zebesten ofteno®) on inflammation of the conjunctival surface in subjects with grade I-III pterygium vs placebo. Hypothesis H0.
- Conditions
- Pterygium, Ocular Pain, Ocular Inflammation, Post-surgical Inflammation
- Trial name
- PRO-155/IV (NCT03521791)
- Testing
- PRO-155
- Where
- 3 sites in Mexico
- Volunteers
- 166 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Inflammation, Pain
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02508337
- Testing
- XG-102
- Where
- United States
- Volunteers
- 309 people
- Sponsor
- Xigen SA
Cataract
A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%
This is a post-approval, open-label, randomized, self-controlled prospective clinical study to evaluate the safety and ocular efficacy of Dexycu in controlling postoperative ocular pain and inflammation associated with cataract…
- Trial name
- NCT04273282
- Testing
- Dexycu intracameral dexamethasone, Prednisolone Acetate
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Research Insight LLC
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.
Ocular Inflammation and Pain
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone…
- Trial name
- NCT01666210
- Testing
- OTX-DP (Dexamethasone punctum plug)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ocular Therapeutix, Inc.
Chronic Ocular Pain
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and…
- Trial name
- NCT04630158
- Testing
- SAF312
- Where
- 28 sites in United States, Japan and 1 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals